‘Science 2022 Top Employer List’ recognises two Indian pharma companies

 02-Nov-2022

Biocon Foundation receives the ‘Mahatma Award 2022 For Excellence in Social Good’

 08-Oct-2022

Never let gender come in the way of your ambitions, dream big: Kiran Mazumdar-Shaw at Yuva Unstoppable event

03-Oct-2022

Biocon’s growth drivers are in place: 5 reasons it is this week’s stock pick

03-Oct-2022

Want to be remembered more than just woman of science: Kiran Mazumdar-Shaw

25-Sep-2022

Mazumdar-Shaw awarded H.K. Firodia Lifetime Achievement Award 2022

25-Sep-2022

Biocon CEO says no intention to sell further stake in Syngene

 07-Sep-2022

Biocon Biologics’ Malaysian unit enters Malaysia Book of Record

 05-Aug-2022

Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

 06-July-2022

Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

 05-July-2022

Biocon Biologics expects big gains from integration of Viatris business, SII deal

 09-June-2022

Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

Biocon arm to buy US company Biosimilar biz for $3.34 billion

01-Mar-2022

Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

24-Jan-2022

Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

22-Jan-2022